Drug Patents owned by Clivunel Inc

1. Drug name - SCENESSE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10076555 CLIVUNEL INC Methods of inducing melanogenesis in a subject Feb, 2025

(2 years from now)

US8334265 CLIVUNEL INC Method of treatment of photodermatoses Mar, 2029

(6 years from now)

Drugs and Companies using AFAMELANOTIDE ingredient

Treatment: Increase pain-free light exposure in adult patients with a history of phototoxic reactions from erythropoietic protoporphyria (epp)

Dosage: IMPLANT;SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
16MG IMPLANT;SUBCUTANEOUS Prescription

availability in other generic markets.

Click on the highlighted region to filter.